

## Type 2 Diabetes in adults (medicines update) Committee meeting 6

**Date:** 14/11/2023

**Location:** Virtual

**Minutes:** Final

**NICE** National Institute for  
Health and Care Excellence

<b>Committee members present:</b>	
Waqaar Shah (Chair)	Present for notes 1 – 8
Chirag Bakhai	Present for notes 1 – 8
Mimi Chen	Present until partway through item 3
Sithembile Thokozile Chinaire	Present for notes 1 – 8
Hussain Contractor	Present for notes 1 – 8
Natasha Jacques	Present for notes 1 – 8
Sallianne Kavanagh	Present for notes 1 – 8
Sharon McCarthy	Present for notes 1 – 8
Soon Song	Present for notes 1 – 8
Annette Swinkels	Present for notes 1 – 8
Dominic Taylor	Present for notes 1 – 8
John Turner	Present for notes 1 – 8

<b>In attendance:</b>		
Astrid Aregui	Senior Medical Editor	Present for notes 1 – 6
Jackie Durkin	Administrator	Present for notes 1 – 3
Sarah Dwyer	Technical Analyst	Present for notes 1 – 8
Linyun Fou	Technical Analyst	Present for notes 1 – 4
Sarah Glover	Information Specialist	Present for notes 1 – 8
James Hawkins	Senior Health Economist	Present for notes 1 – 8
Lina Manounah	Technical Analyst	Present for notes 1 – 5
Sarah Matthews	Technical Analyst	Present for notes 1 – 4
Caroline Mulvihill	Technical Adviser, Guideline Lead	Present for notes 1 – 8
Tayyaba Mumtaz	Trainee Technical Analyst	Present for notes 1 – 8

Sade Naku	Health Economist	Present for notes 1 – 8
Adam O’Keefe	Project Manager	Present for notes 1 – 8
Nancy Pursey	Trainee Technical Analyst	Present for notes 1 – 4
Emily Terrazas-Cruz	Senior Research Fellow	Present for notes 1 – 8
Philip Williams	Finance Analyst	Present for notes 1 – 8
George Wood	Senior Technical Analyst	Present for notes 1 – 8

<b>External in attendance:</b>	
Beatrice Downing, NICE Guidelines Technical Support Unit, University of Bristol	Present for notes 1 – 8
Hugo Pedder, NICE Guidelines Technical Support Unit, University of Bristol	Present for notes 1 – 8

<b>Apologies:</b>	
Neel Basudev	Committee member
Catherine Bewsey	Committee member
Dan Cuthbertson	Topic Adviser
Anne Dornhorst	Committee member
Hugh Gallagher	Committee member
Gosia Wamil	Committee member
Rupert Franklin	Senior Guideline Commissioning Manager, NICE
Muksitur Rahman	Health Economist, NICE

<b>1. Welcome, introductions and apologies</b>
<p>The Chair welcomed the Committee members and attendees, including colleagues from the NICE Guidelines Technical Support Unit at University of Bristol to the fifth meeting on Type 2 Diabetes in adults (medicines update). The Chair informed the Committee that apologies had been received. These are noted above.</p> <p>The Chair welcomed newly appointed committee member Hussain Contractor to their first meeting.</p>
<b>2. Confirmation of matter under discussion, and declarations of interest</b>
<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initial and subsequent treatment of type 2 diabetes.</p> <p>The Chair asked committee members to verbally declare any new interests, these are noted below:</p>

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Chirag Bakhai	Committee member, GP	Co-author of Minor Illness Manual 6th Edition (due to be published in February 2024). Not Diabetes specific and not industry sponsored.	Direct, non-financial professional and personal	Declare and participate. Not specific to the scope of the guideline update
Hussain Contractor	Committee member, Consultant Cardiologist	Talk at RCGP conference on cardiovascular risk and CKD, sponsored by Boehringer. Not specific to diabetes but was about updated license for empagliflozin in CKD.	Direct financial	Declare and participate. Not specific to the scope of the guideline update
Dominic Taylor	Committee member, Consultant Nephrologist	Sub-PI on AZ DIALYZE-OUTCOMES study of sodium zirconium cyclosilicate (SZC) for treatment of hyperkalaemia for patients on dialysis.	Direct, non-financial professional and personal	Declare and participate. Not specific to the scope of the guideline update

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### 3. Minutes of previous meeting

One minor amendment was requested to the attendee list but the minutes of the previous meeting were otherwise accepted as a true and accurate record.

### 4. Review Question 1.2 Which pharmacological therapies are most clinically and cost effective for the management of type 2 diabetes when current treatment has not given adequate response?

The chair introduced Linyun Fou, Sarah Matthews and Nancy Pursey, Technical Analysts, who provided the committee with a refresher of the clinical evidence presented at the previous meeting in support of Review Question 1.2 for Heart failure and chronic kidney disease outcomes. The committee discussed the evidence presented to it but decided not to draft any recommendations at this stage. The

committee also discussed health inequalities considerations raised.

**5. Review Question 1.1 For different population subgroups, which individual and/or combinations of pharmacological therapies are most clinically and cost effective as initial treatment for the management of type 2 diabetes?**

The Chair welcome Beatrice Downing and Hugo Pedder from NICE's Guidelines Technical Support Unit at University of Bristol, who presented the committee with further preliminary outputs from the Network Meta-Analyses being produced in support of Review Question 1.1. The committee discussed the evidence presented to them though decided not to draft any recommendations at this stage. The committee also discussed health inequalities considerations raised.

**6. Review Question 1.2 Which pharmacological therapies are most clinically and cost effective for the management of type 2 diabetes when current treatment has not given adequate response?**

**- Cardiovascular outcomes**

The chair introduced Sarah Dwyer and Tayyaba Mumtaz, Technical Analysts, who presented clinical evidence identified in support of Review Question 1.2 for cardiovascular disease outcomes. Sade Naku (SN), Health Economist then discussed the health economics in this area with the committee. The committee discussed the evidence presented to it and drafted recommendations accordingly.

**7. Health economics**

The Chair introduced James Hawkins, Senior Health Economist and reintroduced SN, who presented the Health economic modelling approach, utilities and costs as discussed at the health economics sub-group meeting.

**8. AOB**

Adam O'Keefe, Project Manager (AO) outlined next steps before the Chair thanked participants and closed the meeting.

**Date of next meeting:** Guideline Committee Meeting 7: 12 & 13 December 2023

**Location of next meeting:** Virtual